Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue

Ye Zhou, Maya Otto-Duessel, Miaoling He, Susan Markel, Tim Synold and Jeremy O Jones

Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Road, Beckman 2310, Duarte, California 91010, USA

Correspondence should be addressed to J O Jones
Email jjones@coh.org

Abstract

Prostate cancer (PC) is both an age- and an androgen-dependent disease. Paradoxically, systemic levels of androgens decline with age as the risk of PC rises. While there is no correlation between systemic androgen levels and the risk of PC, systemic androgen levels do not reflect the levels of androgens in prostate tissue. In metastatic PC, changes in the androgen biosynthesis pathway during hormone therapy result in increased levels of androgens in cancer tissue and contribute to continued androgen receptor (AR) signaling. It is possible that similar changes occur in normal prostate tissue as androgen levels decline with age and that this contributes to tumorigenesis. In the present study, we sought to determine whether the rat prostate is able to maintain functional levels of androgens despite low serum testosterone levels. Rats were castrated and implanted with capsules to achieve castrate, normal, sub-physiological, and supra-physiological levels of testosterone. After 6 weeks of treatment, LC–MS/MS was used to quantify the levels of testosterone and dihydrotestosterone (DHT) in the serum and prostate tissue. Quantitative RT-PCR was used to quantify the expression of genes involved in the androgen/AR signaling axis. Despite significantly different levels of testosterone and DHT being present in the serum, testosterone and DHT concentrations in prostate tissue from different testosterone-treatment groups were very similar. Furthermore, the expression of androgen-regulated genes in the prostate was similar among all the testosterone-treatment groups, demonstrating that the rat prostate can maintain a functional level of androgens despite low serum testosterone levels. Low-testosterone treatment resulted in significant alterations in the expression of androgen biosynthesis genes, which may be related to maintaining functional androgen levels.

Key Words

- androgen
- prostate
- prostate cancer
- androgen receptor

Introduction

Androgens and the androgen receptor (AR) signaling pathway are intimately associated with prostate carcinogenesis, and androgen deprivation therapy remains the most effective way to prevent the growth of metastatic prostate cancer (PC; Miyamoto et al. 2004). However, the relationship between androgen levels and the initiation of PC is still unclear. The risk of PC, an androgen-dependent disease, is highly associated with age, but serum levels of androgens are known to decline with age (Feldman et al. 2002). Many groups have studied the relationship between
serum androgen levels and PC risk, and the consensus is that elevated systemic androgen levels do not correlate with PC incidence (Roddam et al. 2008, Morgentaler 2009). However, several cross-sectional studies have found that a low testosterone level at the time of PC diagnosis is correlated with a more aggressive disease (Schatzl et al. 2001). Additionally, in one of the largest and most thorough analyses to date, low serum dihydrotestosterone (DHT) levels have been associated with an increased risk of PC (Goldenberg et al. 2011). Furthermore, a study in a genetically engineered mouse model of human cancer (Nkx3-1; Pten mutant mouse) has shown that prolonged exposure to low levels of testosterone accelerates tumor progression and leads to a more aggressive disease than exposure to normal or castrate levels of testosterone (Banach-Petrosky et al. 2007). While these studies are far from conclusive, it appears that low systemic androgen levels may be associated with an increased risk of PC incidence and aggressiveness.

A major shortcoming of all of these studies is that they used serum androgen levels as a surrogate for prostate tissue androgen levels. It has been clearly demonstrated that prostate and PC tissues are only modestly influenced by serum levels of androgens. Studies on the molecular impact of testosterone replacement therapy (TRT) as well as of male hormonal contraception on intraprostatic androgen concentration and androgen action indicate that the intraprostatic level of androgen is not affected by testosterone supplementation (Marks et al. 2006, Page et al. 2006, Morgenthaler & Traish 2009, Goldenberg et al. 2011, Mostaghel et al. 2012). A small study in medically castrated healthy men has further revealed that despite a 94% decrease in serum testosterone levels with medical castration, intraprostatic testosterone and DHT levels remain 20–30% of the control values and that prostate cell proliferation, apoptosis, and androgen-regulated protein expression are not affected (Page et al. 2006). These results suggest that the prostate may behave like a buffer that can maintain the intraprostatic level of androgen despite a wide range of serum levels. However, how the prostate buffers androgen concentrations in the milieu of a wide range of systemic androgens is still unclear.

A similar phenomenon occurs in metastatic PC tissue where, despite castrate levels of androgens in the blood, testosterone and DHT levels in the cancer tissue are sufficient to activate AR signaling and drive cancer growth (Nadiminty & Gao 2012). Several mechanisms have been proposed to explain the continued AR signaling in castration-resistant PC (CRPC), chief among them are the changes that allow for the increased uptake of adrenal androgens (Bosland 2000, Chen et al. 2004, Labrie et al. 2005, Stanbrough et al. 2006, Nadiminty & Gao 2012), de novo intracellular androgen synthesis (Locke et al. 2008, Montgomery et al. 2008, Cheng et al. 2010, Nadiminty & Gao 2012), and downregulation of steroid metabolism (Soronen et al. 2004), as well as amplification and over-expression of the AR and its splice variants (Chen et al. 2004, Guo et al. 2009, Waltering et al. 2009, Hornberg et al. 2011, Shiota et al. 2011). We reasoned that many of the same mechanisms may be responsible for the ability of the normal prostate to maintain relatively constant levels of testosterone and DHT despite a wide range of androgens in the blood, especially in the setting of a low-testosterone environment, which is often observed in older men.

To test our hypothesis, we first sought to determine whether the rat prostate could be used to model intraprostatic androgen maintenance. We also comprehensively examined the expression of genes in the androgen/AR signaling pathway to determine whether changes in these genes correlated with the ability of the rat prostate to maintain androgen levels. We found that the normal rat prostate, much like the CRPC tissue, has altered expression of genes in the androgen/AR signaling axis in response to low serum testosterone levels, which results in the ability of the prostate to sustain functional intraprostatic androgen levels.

Materials and methods

Animal protocol

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and was approved by the City of Hope IACUC (11036). A total of 28 male Sprague–Dawley rats (8 weeks old, postpubertal) were purchased from Harlan Laboratories (Indianapolis, IN, USA) and were fed water and rat chow ad libitum. A cohort of rats (n = 4) was kept intact as a control for the experiments. The remaining rats were randomly divided into four groups (six rats/group) and castrated to eliminate the endogenous source of androgens. The manipulation of testosterone was achieved using silastic capsules, which were implanted subcutaneously via a small skin incision at the same time as castration. Testosterone was purchased from Steraloids (Newport, RI, USA). According to published results, testosterone capsules were designed to have a release rate
of 11.5 μg/day for the testosterone 0.5 cm group, 46 μg/day for the testosterone 2 cm group, or 110 μg/day for the testosterone 5 cm group, which allowed us to administer sub-physiological, normal, or supra-physiological levels of testosterone (Moger 1976, Vanderschuren et al. 2000). Six weeks later, the rats were killed, serum was collected by cardiac puncture, and testosterone and DHT levels were measured using HPLC–MS/MS. Prostates were also harvested, weighed, and prepared for gene expression analysis or immediately frozen for the measurement of testosterone and DHT concentrations.

**Androgen concentration measurements**

Testosterone and DHT concentrations were determined by mass spectrometry using methods adapted from those that have been described previously (Montgomery et al. 2008). In brief, frozen tissue samples were individually thawed, weighed, and homogenized in H2O at a concentration of 100 mg/ml. Later, 100 μl of homogenates or serum were spiked with internal standard 3-deuteride-testosterone (testosterone-d3) and DHT-d3, diluted with 400 μl water, and extracted with 5 ml hexane. The organic phase was transferred and evaporated to dryness. Each individual concentrated extract was dissolved in 0.1 M hydroxylamine hydrochloride in 50% methanol/water and incubated for 1 h. Standards for DHT and testosterone were prepared in parallel. The resulting oximes were analyzed by HPLC–MS/MS using an Agilent Technologies LC 1100 series system (Palo Alto, CA, USA) interfaced with a Micromass Quattro Ultima Triple Quadrupole Mass Spectrometer (Micromass, Inc., Milford, MA, USA). MassLynx version 4.1 Software (Micromass) was used to acquire and analyze data. Separation of analytes was achieved on a Kinetex 2.6 μm 100×2.1 mm C18 column (Phenomenex, Torrance, CA, USA). Ions monitored were m/z 304.5>124.25 and 307.5>112.25 for testosterone and testosterone-d3 respectively and m/z 347.55>306.45 and 350.55>309.45 for DHT and DHT-d3 respectively. Limits of detection (defined as a S/N ≥5) for testosterone and DHT were 0.02 and 0.01 ng/ml respectively.

**Estradiol and DHEA ELISAs**

DHEA and estradiol (E2) concentrations were determined by ELISA (DHEA: APLCO, Salem, NH, USA; E2: Diagnostic Automation, Inc., Calabasas, CA, USA). The sensitivities of the DHEA and E2 ELISAs were 0.02 and 0.01 ng/ml respectively. and DHT were 0.02 and 0.01 ng/ml respectively.

<0.1%, and the cross-reactivity of the E2 assay with other steroids is <2%. The measurable ranges for DHEA and E2 are 0–30 ng/ml and 0–1000 pg/ml respectively.

**RNA isolation and quantitative RT-PCR**

Total RNA was isolated using a PARIS kit (Ambion, Carlsbad, CA, USA), followed by treatment with DNase using the Qiagen RNase–Free DNase Set (Qiagen, Inc.). cDNA was generated from each sample using 250 ng of total RNA in an oligo dT-primed RT reaction. Quantitative RT-PCRs (qRT-PCRs) were performed in triplicate using a StepOne Real Time PCR system (Applied Biosystems) with ~2.5 ng of cDNA, 1 μM of each primer pair, SYBR Green (Invitrogen) as the detecting dye, Rox (Invitrogen) as the reference dye, and Taq PCR kit (Qiagen, Inc.). Primers specific for the genes of interest were designed using the web-based primer design service PrimerQuest provided by Integrated DNA Technologies (Coralville, IA, USA). To analyze Ar variant mRNA expression, we adapted the primers previously reported specific to AR splice variants in humans (Dehm et al. 2008, Guo et al. 2009, Hu et al. 2009b, Sun et al. 2010). Sequences are provided in Supplementary Table 1, see section on supplementary data given at the end of this article.

**Cloning and sequencing of Ar variant transcripts**

For each sample, 2% cDNA product from 250 ng of input total RNA was used. PCR products derived from the primer pairs that span the region of exons 1–3 and 1–8 of the Ar gene (Supplementary Table 1) were cloned into TopoTA vector (Invitrogen) and subjected to a sequencing analysis at the DNA sequencing core facility (Hope of 1).**

**Statistical analysis**

The serum and tissue androgen concentrations are expressed as mean ± S.D. The significance of differences was determined using ANOVA followed by a Tukey's correction. P values <0.05 were considered significant. For the analysis of the qRT-PCR data, the mean cycle threshold (Ct) obtained for each gene was normalized to the expression of the housekeeping gene Rpl19 in the same sample (the ΔCt). The specificity of amplification in each reaction was assessed based on the melting point of the dissociation curve. The fold change was calculated by taking the inverse log of the difference in mean ΔCt values between the treatment groups and the intact group.
One-way ANOVA followed by a Tukey’s correction was used for planned comparisons between the treatment groups that were defined by linear contrast statements. A P value <0.05 was considered significant.

**Results**

**Functional levels of androgens are maintained in the prostate despite low serum testosterone levels**

To determine the relationship between serum and prostate tissue androgen levels in rats, rats were castrated to remove the endogenous source of testicular androgens and implanted with silastic capsules for delivery of zero, low, normal, or high levels of testosterone. We maintained a group of rats that had not been castrated or otherwise manipulated, which provided a control for the endogenous levels of testosterone and DHT (the intact group). After 6 weeks, the serum and intraprostatic concentrations of testosterone and DHT were assessed by LC–MS/MS analysis.

The serum and prostate tissue levels of testosterone and DHT in each rat are shown in Fig. 1. Intact rat serum testosterone levels were 4.48 ± 1.72 ng/ml and DHT levels were 0.18 ± 0.09 ng/ml. Serum DHT levels were below the level of detection (0.03 ng/ml) in all the castrated rats and serum testosterone levels were below the level of detection in two of six rats, with the remainder exhibiting levels averaging only 0.04 ng/ml. The values of testosterone levels were corroborated by ELISA (data not shown). We observed a linear correlation between the size of testosterone implant and serum testosterone and DHT levels, as expected. While the normal testosterone-treated group had similar serum testosterone and DHT levels compared with the intact group (3.98 ± 1.63 ng/ml for testosterone and 0.09 ± 0.03 ng/ml for DHT), serum levels of testosterone (1.30 ± 0.25 ng/ml, P=0.0305) and DHT (0.02 ± 0.02 ng/ml, P=0.0171) were significantly lower in the low-testosterone-treated group than in the intact group. The group receiving high-testosterone implants had serum testosterone (9.95 ± 2.77 ng/ml, P<0.0001) and DHT (0.26 ± 0.14 ng/ml, P<0.0001) concentrations significantly higher than those in the intact group or in rats receiving either low or normal doses of testosterone. The differences in serum androgen levels were reflected in the wet weight of the prostates, although these differences were not statistically significant when compared with those of the intact group (Fig. 1E). High-testosterone treatment resulted in widespread hypertrophy as indicated by increased glandular folding and hyperchromatic nuclei (Fig. 1I, compare with intact in H), while castration resulted in severely atrophied and compact glands devoid of secretory cells (Fig. 1J). The low-testosterone-treated rat prostates had multiple atrophic foci, as evidenced by glands with flattened epithelial layers (Fig. 1K), but there were no other major abnormalities in the low-testosterone-treated rat prostates.

While serum testosterone and serum DHT levels were correlated (r=0.87), neither prostate testosterone nor prostate DHT levels correlated with serum testosterone levels (r=0.06 and r=−0.02 respectively). Despite varied serum androgen levels, intraprostatic concentrations of testosterone and DHT were not significantly different among the treatment groups (Fig. 1F). Although the serum levels of testosterone and DHT in the low-testosterone group were only 29 and 12% of those in the intact group, the levels of testosterone and DHT in the prostates of the low-testosterone group were 64 and 71% as much as those in the prostates of the intact group. A converse phenomenon was observed in the high-testosterone group. Although serum levels were markedly higher, tissue levels of testosterone and DHT were only 29 and 58% of those in the intact group – lower than those in the low-testosterone group. Although these comparisons were made on a per-milligram-of-tissue basis, adjusting for prostate size to calculate the total androgenic content of the prostate in each rat led to the same conclusions. Our results are consistent with those of other studies that have shown that the relationship between serum and prostate tissue levels of androgens is not linear. Furthermore, the levels of androgens in the prostate of all the testosterone-treatment groups appeared to be functional as there was no significant difference in the expression of androgen-regulated genes among the groups, while the expression of these genes was significantly different in the castrated group (Fig. 1G). Our results suggest that the rat prostate can preserve functional levels of testosterone and DHT despite low serum levels and is, therefore, an adequate model for studying the mechanism of intraprostatic androgen maintenance.

**Altered expression of AR and genes mediating androgen uptake in the low-testosterone environment**

To investigate the mechanisms responsible for the maintenance of androgens in the prostate in the setting of low serum testosterone levels, we used qPCR to quantify the expression of genes known to be involved in the androgen/AR signaling axis (Table 1 and Supplementary Table 1). We first examined the expression of AR and
known steroid-transporter genes including the Slco gene family (Slco2b1, Slco1b3, Slco1a5, and Slco2a1), androgen-binding protein (Abp (Shbg)), which is the homolog of the human steroid hormone-binding globulin (SHBG) gene, and LDL-related protein 2 (Lrp2, or megalin). Notably, in the low-testosterone group, AR expression was increased ($P=0.0099$), while AR expression in other groups was comparable to that in the intact group.

Figure 1
Serum and prostate tissue levels of androgens. The levels of serum testosterone (A), serum DHT (B), prostate testosterone (C), and prostate DHT (D) are shown for each rat. (E) Average wet prostate weight of each treatment group. (F) The average concentration of testosterone and DHT in each treatment group compared with that in the intact group. (G) Relative gene expression for a panel of androgen-responsive genes in the prostates of each treatment group compared with that in the intact group. Though serum androgen levels were vastly different, prostate tissue androgen levels were very similar in all the testosterone-treatment groups, leading to equivalent androgen-dependent gene expression. (H, I, J and K) Representative H&E (20× magnification) staining of intact (H), high-testosterone (I), castrated (J), and low-testosterone (K) rat prostates. Statistically significant differences in the intact group (ANOVA, $P<0.05$) are indicated by *.
This suggests that there is pressure to increase AR expression in normal prostate in response to low serum testosterone levels in rats (Cutler et al. 1978). Furthermore, we were not able to detect any DHEA in the rat prostate tissue by ELISA. However, it appears that the increased expression of Slco2b1 is not important for the ability of the rat prostate to maintain androgen levels in our low-testosterone-treated group as its expression in these rats was very similar to that in the intact group. Although we found slight increases in the levels of expression of Lrp2 as well as Abp in response to low serum testosterone levels, the changes were not significant (Lrp2, \( P = 0.4272 \); Abp, \( P = 0.1218 \)).

### Table 1

<table>
<thead>
<tr>
<th>Genes</th>
<th>Low testosterone (P value)</th>
<th>Medium testosterone</th>
<th>High testosterone</th>
<th>Castrated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ar</td>
<td>1.7 (0.009)</td>
<td>0.93</td>
<td>1.15</td>
<td>0.96</td>
</tr>
<tr>
<td>Slco2b1</td>
<td>1.1 (0.998)</td>
<td>0.82</td>
<td>0.69</td>
<td>4.48*</td>
</tr>
<tr>
<td>Abp</td>
<td>1.87 (0.121)</td>
<td>1.00</td>
<td>1.72</td>
<td>0.59</td>
</tr>
<tr>
<td>Lrp2</td>
<td>1.8 (0.427)</td>
<td>1.02</td>
<td>0.98</td>
<td>1.50</td>
</tr>
<tr>
<td>Hsd3b1</td>
<td>2.03 (0.042)</td>
<td>1.36</td>
<td>1.16</td>
<td>0.40</td>
</tr>
<tr>
<td>Hsd17b1</td>
<td>2.74 (0.008)</td>
<td>1.91</td>
<td>2.06</td>
<td>1.22</td>
</tr>
<tr>
<td>Hsd17b3</td>
<td>3.67 (0.029)</td>
<td>2.98</td>
<td>2.76</td>
<td>3.21</td>
</tr>
<tr>
<td>Hsd17b6</td>
<td>2.92 (0.005)</td>
<td>1.19</td>
<td>0.52</td>
<td>0.16</td>
</tr>
<tr>
<td>Rdh5</td>
<td>2.25 (0.041)</td>
<td>2.04</td>
<td>1.60</td>
<td>1.37</td>
</tr>
<tr>
<td>Slrd5a3</td>
<td>1.68 (0.083)</td>
<td>1.46</td>
<td>1.59</td>
<td>0.80</td>
</tr>
<tr>
<td>Hsd17b7</td>
<td>1.06 (0.998)</td>
<td>0.98</td>
<td>1.23</td>
<td>0.33*</td>
</tr>
<tr>
<td>Hsd17b10</td>
<td>1.56 (0.015)</td>
<td>0.98</td>
<td>1.27</td>
<td>0.97</td>
</tr>
<tr>
<td>Cyp19a1</td>
<td>1.60 (0.037)</td>
<td>1.20</td>
<td>1.37</td>
<td>0.83</td>
</tr>
<tr>
<td>Sult1e1</td>
<td>3.32 (0.112)</td>
<td>1.85</td>
<td>1.21</td>
<td>0.69</td>
</tr>
<tr>
<td>Hsd17b2</td>
<td>3.07 (0.140)</td>
<td>2.14</td>
<td>2.13</td>
<td>1.98</td>
</tr>
<tr>
<td>Gusb</td>
<td>4.06 (0.635)</td>
<td>3.50</td>
<td>1.98</td>
<td>2.72</td>
</tr>
<tr>
<td>Arsc1</td>
<td>1.72 (0.081)</td>
<td>1.30</td>
<td>1.21</td>
<td>1.20</td>
</tr>
</tbody>
</table>

### Discussion

The complex relationship between serum and prostate tissue androgen levels and the risk of PC is not well...
understood. Here, we confirm the results of other studies that have shown that the rat can provide a useful model for understanding the relationship between serum and prostate tissue androgen levels (Kyprianou & Isaacs 1987a). We found that despite a wide range of serum testosterone levels, the levels of androgens in the prostate were fairly constant and not related to serum testosterone levels, which has been shown previously by Kyprianou & Isaacs (1987b). Kyprianou & Isaacs treated castrated rats with various sizes of silastic testosterone capsules to demonstrate that ‘androgen-induced increase in prostatic cell number occurs as a quantal process that can only begin when the concentration of prostatic DHT is above a critical threshold value (i.e. 0.4 ng/10⁸ cells for the rat ventral prostate)’. We anticipate that a similar threshold exists for maintaining androgen-dependent signaling in the prostate and, furthermore, that a threshold exists for the concentration of blood androgens necessary to maintain tissue androgens. We also suspect that this threshold impacts tumorigenesis because in the Nkx3-1/Pten knockout model, castration reduces PC incidence but low testosterone levels increase the incidence (Abate-Shen et al. 2003).

Our findings in rats also parallel previous findings in humans (Page et al. 2006, Morgentaler 2009, Morgentaler & Traish 2009, Goldenberg et al. 2011). Page et al. (2011) found that either medical castration or androgen supplementation in healthy men resulted in substantial changes in serum testosterone levels, while intraprostatic testosterone or DHT concentrations were relatively unaffected. Likewise, in a study of 44 men, Marks et al. (2006) demonstrated that 6 months of TRT normalizes serum androgen levels but does not affect prostate tissue androgen levels and cellular functions. In the setting of PC, several studies have found that intraprostatic androgen levels are preserved despite castrate serum

Figure 2
Changes in steroid biosynthesis pathway leading to testosterone and DHT accumulation. Genes in which statistically significant changes occurred in the low-testosterone-treated rats vs intact rats are in bold. These changes would be predicted to lead to increased levels of testosterone and DHT.
testosterone and DHT levels following androgen deprivation therapy (Mohler et al. 2004, Montgomery et al. 2008). Moreover, these levels of intraprostatic androgens are sufficient to maintain important biological processes within the gland as evidenced by the continued expression of androgen-regulated genes. Likewise, we found that androgen levels in the prostates of the low-testosterone-treated rats were sufficient to maintain the expression of androgen-regulated genes. Together, these data support the hypothesis that in humans and rats, serum androgen levels are not equivalent to prostate tissue androgen levels and that the prostate is able to adapt to variable androgen environments to maintain a functional level of androgens.

In humans, several mechanisms have been shown to contribute to androgen maintenance in the setting of CRPC, many of which may be relevant in intraprostatic androgen maintenance in healthy human and rat prostates as well. Chen et al. (2004) have shown that increased AR expression is instrumental in the progression from androgen-dependent to castration-resistant growth, with the degree of AR upregulation observed being sufficient to allow tumor cell proliferation in 80% lower androgen concentrations. We also observed a slight but significant increase in the expression of AR when the prostate was exposed to a low systemic testosterone environment. While this certainly contributes to maintaining AR-dependent signaling, it could also contribute to the increased prostate tissue androgen levels by simply increasing the amount of androgens bound and retained in the prostate. However, the slight increase in AR expression, the estimated femtomolar concentration of AR, and the presence of a plethora of other ABPs in the prostate suggest that increased androgen retention is not the major mechanism of androgen maintenance in normal rat prostate tissue.

Increased uptake of androgens from the serum is another potential contributor to intraprostatic androgen maintenance. We assessed several genes reported to mediate androgen delivery and uptake in humans, but found none to be significantly altered in the setting of a low-testosterone environment. We did, however, observe slight increases in the expression of Aqp and megalin. It is possible that with larger cohorts of animals, these values would have reached statistical significance. ABP, the SHBG homolog, is a well-characterized plasma protein that regulates the level of bioavailable androgens in the blood and has also been shown to be produced by prostate cells and to facilitate androgen entry into cells via interaction with endocytic receptors such as megalin (Hammes et al. 2005), signaling receptors that remain to be identified (Heinlein & Chang 2002, Kahn et al. 2008), or proteins in the extra-cellular matrix, such as fibulin (Ng et al. 2006). Thus, the increased expression of ABP/SHBG and its receptors such as megalin in prostate tissue may contribute to the cellular uptake of steroid hormones and intraprostatic androgen maintenance.

In addition to the uptake of circulating testosterone and DHT, the conversion of circulating adrenal androgen precursors, primarily DHEAS, has also been reported as a potential source of prostate androgens in CRPC tissue (Bartsch et al. 1990, Labrie et al. 2001, Stanbrough et al. 2006). However, in agreement with previous studies that indicate that rodent species only have very low levels of circulating DHEAS due to a lack of adrenal CYP17 (CYP17A1) expression (Cutler et al. 1978, Ando et al. 1988, Hu et al. 2009a), we could not detect any DHEA in the serum or prostate by ELISA. While an unknown adrenal androgen could contribute to the androgenic content of the rat prostate, the fact that testosterone and DHT were not detected in prostates from castrated rats argues against an adrenal androgen source, since the adrenal gland was intact in these rats. Thus, at least in rats, conversion of adrenal androgens does not appear to contribute to intraprostatic androgen maintenance.

We did observe many significant changes in the expression of enzymes involved in the biosynthesis and metabolism of androgens in response to low serum testosterone levels. Many of these changes were very similar to those that have been reported in PC cells as they transition to castration resistance. We observed an upregulation of the expression of Hsd3b1, Hsd17b1, Hsd17b3, Hsd17b6, Rdh5, Hsd17b10, and Srd5a3, all of which would be expected to lead to an increase in testosterone and DHT levels (Fig. 2). In one of the most comprehensive studies to date, Montgomery et al. (2008) observed a similar upregulation in the expression of several of these enzymes in castration-resistant vs androgen-sensitive PC tissue. They also observed a decrease in SRD5A2 expression and an increase in SRD5A1 expression. While we did not observe significant changes in these genes, we did find a significant increase in the expression of Srd5a3, the gene encoding an enzyme that can mediate the same conversion of androgens to their 5α metabolites (Uemura et al. 2008). This alternative enzyme usage might be specific to rats vs humans or to the process of intraprostatic androgen maintenance vs the process of castration resistance. Of note, we did not observe the expression of any unusual Ar transcripts or AR splice variants, as has been reported in CRPC tissue (Guo et al. 2008).
2009, Hu et al. 2009b, Hornberg et al. 2011). This suggests that the expression of AR splice variants may be unique to humans and/or the process of castration resistance. The altered expression of genes encoding enzymes in the androgen biosynthesis pathway suggests that increased synthesis of androgens in the prostate may be a major factor in androgen maintenance in the rat prostate in a low systemic testosterone environment, much as it is in the setting of CRPC. Whether the normal rat prostate can synthesize testosterone and DHT de novo from cholesterol remains to be determined.

The Montgomery study also noted significant changes in the metabolic enzymes responsible for the conjugation of glucuronide to androgens, UGT2B15 and UGT2B17. These proteins do not have direct homologs in rats, but we did observe changes in the expression of two genes involved in the sulfate and glucuronide metabolic pathways: Gusb, which encodes the β-glucuronidase enzyme responsible for the hydrolysis of steroid glucuronides, and Arsc1, which encodes the enzyme responsible for the hydrolysis of E2-3-sulfate as well as DHEAS. Of note, the expression of β-glucuronidase has been reported to be increased in prostate carcinoma compared with in prostatic hyperplasia (Pearson et al. 1989). Thus, it is possible that these metabolic enzymes participate in the maintenance of intraprostatic androgens.

The Montgomery study also noted a strong increase in the expression of CYP19A1, the gene encoding aromatase. We also observed a significant increase in the expression of Cyp19a1, as well as an increased expression of Sult1e1 and Hsd17b1, genes encoding enzymes involved in the estrogen synthesis pathway (Falany et al. 1995, Labrie et al. 1997, Ghosh et al. 2009). These changes should lead to increased concentrations of estrogens in the prostate; however, levels of E2 were below the level of detection by ELISA in rat prostates in our study. Tissue estrogen levels have not been comprehensively examined in the setting of CRPC, but several studies have shown that E1 and E2 are not the major estrogens in the prostate and PC tissue (Krieg et al. 1993, Shibata et al. 2000). As aromatase expression and estrogens have been implicated in the development of PC (Kozak et al. 1982, Krieg et al. 1993, Thompson et al. 2002, Ellem & Risbridger 2010), there is need for further exploration of estrogens in the response to low systemic testosterone levels and in prostate tumorigenesis as well as the development of CRPC.

While the rat model of intraprostatic androgen maintenance has important limitations including differences between the rodent and human endocrine systems and prostate structure (Cutler et al. 1978, Sharma & Schreiber-Agus 1999) and the use of continuous testosterone administration that does not reflect the normal diurnal variation or the gradual decline of systemic androgens with age, our data demonstrate that the healthy rat prostate is able to maintain intraprostatic androgens in the presence of low serum androgen levels through mechanisms similar to those that occur in human CRPC.

Although the development of PC is androgen dependent, the incidence of PC actually increases as systemic androgen levels decline with age. Thus, the relationship between PC and aging suggests that it may be a decrease rather than an elevation of systemic androgen levels that facilitates prostate oncogenesis. However, there is no direct mechanistic evidence supporting this hypothesis. In light of our current findings and the findings of others, one interpretation is that low serum androgen levels may put a selective pressure on the prostate and confer a growth advantage upon cells that maintain androgen levels and active AR signaling. Selection for cell survival in the setting of declining systemic testosterone levels has been proposed previously (Prehn 1999), but here we suggest that instead of changes that lead to the selection of androgen-independent cells, low systemic testosterone levels result in the selection of cells with enhanced sensitivity to androgens and greater dependence on AR signaling. Changes in AR signaling might result in a switch from the regulation of cell differentiation genes to the regulation of growth-stimulatory genes, as occurs in CRPC (Hoimes & Kelly 2010). If such changes occur in prostate stem cells, they could lead to the expansion of proliferation-enabled, AR-dependent cells and lead to distinct cancer foci. While we have demonstrated that changes in the androgen/AR signaling axis probably contribute to intraprostatic androgen maintenance, further studies are required to determine whether and how the mechanisms involved in maintaining intraprostatic androgen levels are responsible for prostate tumorigenesis.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-13-0060.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research was funded in part by NCI CCSG CA033572
References


Heinlein CA & Chang C 2002 The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Molecular Endocrinology 16 2181–2187. (doi:10.1210/me.2002-0070)


Krieg M, Nass R & Tunn S 1993 Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. Journal of Clinical Endocrinology and Metabolism 77 375–381. (doi:10.1210/jc.77.2.375)

Kyprianou N & Isaacs JT 1987a Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10 313–324. (doi:10.1002/pros.2990100405)


Oncogene 18 5349–5355. (doi:10.1088/sj.onc.1203037)

Honma S & Yamanaka H 2000 Changes in the endocrine environment 
of the human prostate transition zone with aging: simultaneous 
quantitative analysis of prostatic sex steroids and comparison with human 
prostatic histological composition. Prostate 42 45–53. 
CO;2-W)

Shiota M, Yokomizo A & Naito S 2011 Increased androgen receptor 
transcription: a cause of castration-resistant prostate cancer and a 
possible therapeutic target. Journal of Molecular Endocrinology 47 

Smith NF, Figg WD & Sparreboom A 2005 Role of the liver-specific 
transporters OATP1B1 and OATP1B3 in governing drug elimination. 
Expert Opinion on Drug Metabolism & Toxicology 1 429–445. 
(doi:10.1517/17425255.1.3.429)

Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, Pulkka A, 
Kurkela R, Herrala A, Kaila J et al. 2004 Sex steroid hormone 
metabolism and prostate cancer. Journal of Steroid Biochemistry and 

Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, 
Febbo PG & Balk SP 2006 Increased expression of genes converting 
adrenal androgens to testosterone in androgen-independent 
(doi:10.1158/0008-5472.CAN-05-4000)

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, 
Page ST, Coleman IM, Nguyen HM, Sun H 2010 Castration resistance in 
human prostate cancer is conferred by a frequently occurring androgen 
(doi:10.1172/JCI41824)

Thompson CJ, Tam NN, Joyce JM, Leav I & Ho SM 2002 Gene 
expression profiling of testosterone and estradiol-17β-induced 
prostatic dysplasia in Noble rats and response to the 
testosterone analogue TICI 182,780. Endocrinology 143 
2093–2105. (doi:10.1210/en.143.6.2093)

Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y & 
Nakagawa H 2008 Novel 5α-steroid reductase (SRD5A3, type-3) is 
overexpressed in hormone-refractory prostate cancer. Cancer Science 
99 81–86.

Vanderschueren D, Vandenput L, Boonen S, Van Herck E, Swinnen JV 
& Bouillon R 2000 An aged rat model of partial androgen deficiency: 
prevention of both loss of bone and lean body mass by low-dose 
adrogen replacement. Endocrinology 141 1642–1647. (doi:10.1210 
/en.141.5.1642)

Waltering K, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA 
& Visakorpi T 2009 Increased expression of androgen receptor sensitizes 
prostate cancer cells to low levels of androgens. Cancer Research 69 
8141–8149. (doi:10.1158/0008-5472.CAN-09-0919)

Received in final form 17 May 2013
Accepted 24 May 2013
Accepted Preprint published online 24 May 2013